参加者へのお知らせとお願い - hpm-net.jp

1 P1 1 3 8 11 00 11 30 3 9 8 10 8 30 2 10,000 3 4 5 6 7 8 3 1 15 2 1 6 3 15 5 P22 PC COI PC 30 1 1 PC OS = Windows XP Windows7 Power Point = Macintosh Macintosh PC Windows format

2 CD-ROM USB MO FD ZIP OS PC 2 PC Windows Macintosh PC D-sub 15pin 3 CD-R USB CD-R USB 1,000 3 8 19 00 35F 1F P2 P3 770-8548 1 1-39 TEL 088-631-0782 FAX 088-632-6885 URL Email P4 P5 3 8 12 00 12 10 12 10 13 20 / 13 20 14 30 /I-HDF14 30 15 30 HDF15 30 15 50 15 50 18 20 19 00 P6 P6 P712:00 12:10 12:10 13.

3 20 / O-01 1 2 3 1 3 1 1 2 3 2 O-02 1 2 3 1 2 2 2 3 1 O-03 2-MG 1-MG 1 2 1 2 2 1 1 1 1 2 O-04 O-05 alpha1-microglobulin(a1m) O-06 ME 1 2 3 1 1 1 1 2 3 O-07 in vitro LDH MT 1 2 1 1 1 1 1 2 P813:20 14:30 /I-HDF O-08 Department of Experimental Medicine and Surgery, University "Tor Vergata", Rome, Italy1 IRCCS-Santa Lucia Foundation, Rome, Italy2 Nephrology Clinical Institute, Department of Medicine, "G.

4 D'Annunzio" University of Chieti-Pescara, Chieti, Italy3 Andrea Urbani 1,2 V Sirolli3 F Abbate1,2 L Pieroni1,2 P Felaco3 S Levi-Mortera1,2 G Fucci1,2 M Bonomini3 O-09 1 2 3 1 1,2 2 2,3 1,2 O-10 1 2 3 1 2 1 1 1 1 1 1 2 3 O-11 TMP On-line HDF 1 2 1 1 1 1 1 2 2 O-12 HDF 1 2 1 1 1 1 1 2 O-13 on-line HDF i-HDF 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 2 2 2 1 P8 P9 O-14 intermittent infusion HDF 1 2 1 1 2 P1014:30 15.

5 30 HDF O-15 HD HDF TMP 1 2 3 1 1 1 1 2 2 3 O-16 HDF O-17 NCV-2 HDF O-18 (PES) MFX-Seco ME 1 2 3 1 1 1 1 1 1 1 1 3 2 O-19 MFX-25U RLS HDF O-20 on-line HDF ME 1 2 1 1 2 1 1 1 1 1 1 2 2 2 2 15:30 15:50 P10 P1115:50 18:20 S-01 S-02 Department of Experimental Medicine and Surgery, University "Tor Vergata", Rome, Italy1 IRCCS-Santa Lucia Foundation, Rome, Italy2 Nephrology Clinical Institute, Department of Medicine, "G.

6 D'Annunzio" University of Chieti-Pescara, Chieti, Italy3 Andrea Urbani 1,2 V Sirolli3 F Abbate1,2 L Pieroni1,2 P Felaco3 S Levi-Mortera1,2 G Fucci1,2 M Bonomini3 S-03 Biopta Co.,Ltd. Dr. Emma Moss Ms Lee Christie Mr Ejaz Ansari Dr. David Bunton S-04 S-05 1 2 3 4 5 6 7 8 9 1 2 3 4 5 6 7 8 1 1 1 9 S-06 E-HOPED STUDY 1 2 1 2 E-HOPED STUDY GROUP19:00 P12 P12 P13 3 9 9 00 10 00 HDF/ 10 00 11 10 HDF/ 11 10 12 10 12 10 13 10 13 10 13 20 13 20 14 20 14 20 15 20 15 20 15 30 P14 P14 P159:00 10.

7 00 HDF/ O-21 on-line HDF ABH-21P O-22 PEPA GDF O-23 GDF-21 O-24 GDF-21 1 2 1 2 1 1 1 1 2 O-25 GDF O-26 on-line HDF GDF-21 P1610:00 11:10 HDF/ O-27 On-line HDF 1 2 3 1 1 2 2 2 3 O-28 on-lineHDF 1 2 3 1 1 1 1 1 2 3 O-29 on-lineHDF O-30 On line HDF 1 2 1 1 2 O-31 On-lineHDF 1 2 3 1 1 1 1 1 1 1 1 1 2 3 3 3 O-32 Alb Alb O-33 1

8 2 1 1 1 1 1 1 2 P16 P1711:10 12:10 O-34 PMMA NF 1 2 1 1 1 1 2 2 2 O-35 1 2 1 1 1 2 1 1 1 1 2 1 1 1 1 2 1 1 1 O-36 PMMA NF 1 2 1 1 1 1 2 2 O-37 PEPA FLX-15GW JA 1 JA 2 1 1 1 1 2 2 2 2 O-38 APS 18EA APS 18 Enew O-39 12:10 13:10 13:10 13:20 P1813:20 14.

9 20 O-40 ATHRITE-BP study 1 2 3 4 5 6 ATHRITE-BP 7 1 1 2 3 4 5 6 7 7 7 7 7 7 1 O-41 1 2 1 1 1 1 1 1 2 O-42 V APEAN-STUDY (UMIN000006439) 1 2 3 4 5 CE 6 7 APEAN-Study Group8 1 2 3 4 5 6 1 7 APEAN-Study Group8 O-43 1 2 3 4 1 1 1 1 1 1 2 3 4 4 4 O-44 PES 2 P18 P19 O-45 P2014:20 15.

10 20 O-46 PMMA NF 1 2 1 1 1 1 1 1 1 1 1 1 1 2 2 2 2 2 O-47 PMMA NF 1 2 3 1 3 1 1 3 2 O-48 PMMA NF 1 2 3 1 1 2 1 3 O-49 PMMA NF 1 2 3 1 1 1 2 1 3 O-50 PMMA NF ME 1 2 3 1 1 1 1 1 1 1 1 1 1 3 2 O-51 PMMA NF-H 1 2 3 4 1 1 2 3 4 15:20 15.